RAAV vectors as safe and efficient tools for the stable delivery of genes to primary human chondrosarcoma cells in vitro and in situ

3Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Treatment of chondrosarcoma remains a major challenge in orthopaedic oncology. Gene transfer strategies based on recombinant adenoassociated viral (rAAV) vectors may provide powerful tools to develop new, efficient therapeutic options against these tumors. In the present study, we tested the hypothesis that rAAV is adapted for a stable and safe delivery of foreign sequences in human chondrosarcoma tissue by transducing primary human chondrosarcoma cells in vitro and in situ with different reporter genes (E. coli lacZ, firefly luc, Discosoma sp. RFP). The effects of rAAV administration upon cell survival and metabolic activities were also evaluated to monitor possibly detrimental effects of the gene transfer method. Remarkably, we provide evidence that efficient and prolonged expression of transgene sequences via rAAV can be safely achieved in all the systems investigated, demonstrating the potential of the approach of direct application of therapeutic gene vectors as a means to treat chondrosarcoma. Copyright © 2012 Henning Madry et al.

Cite

CITATION STYLE

APA

Madry, H., Venkatesan, J. K., Schmitt, G., Schetting, S., Ekici, M., Kohn, D., & Cucchiarini, M. (2012). RAAV vectors as safe and efficient tools for the stable delivery of genes to primary human chondrosarcoma cells in vitro and in situ. Sarcoma, 2012. https://doi.org/10.1155/2012/347417

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free